October 28, 2020 -- Insitro has entered into a five-year agreement with Bristol Myers Squibb for the discovery and development of novel therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
In the collaboration, Insitro will apply its proprietary platform, the Insitro Human (ISH) platform, to create disease models derived from induced pluripotent stem cells (iPSCs) for ALS and FTD. The platform applies machine learning, human genetics, and functional genomics to generate and optimize predictive in vitro models and accelerate therapeutic discovery and development. Bristol Myers Squibb will have the option to select a number of targets identified by Insitro to advance through clinical development and commercialization.
Insitro will receive $50 million in an upfront payment and will be eligible to receive an additional $20 million in near-term operational milestones, totaling more than $2 billion in discovery, development, regulatory, and commercial milestones in addition to clinical development as well as regulatory submissions and commercialization activities.